JP2014508715A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508715A5
JP2014508715A5 JP2013540569A JP2013540569A JP2014508715A5 JP 2014508715 A5 JP2014508715 A5 JP 2014508715A5 JP 2013540569 A JP2013540569 A JP 2013540569A JP 2013540569 A JP2013540569 A JP 2013540569A JP 2014508715 A5 JP2014508715 A5 JP 2014508715A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
agent according
als agent
tnfα monoclonal
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013540569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508715A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2012/056217 external-priority patent/WO2012121403A1/en
Publication of JP2014508715A publication Critical patent/JP2014508715A/ja
Publication of JP2014508715A5 publication Critical patent/JP2014508715A5/ja
Pending legal-status Critical Current

Links

JP2013540569A 2011-03-07 2012-03-06 筋萎縮性側索硬化症の治療方法 Pending JP2014508715A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449753P 2011-03-07 2011-03-07
US61/449,753 2011-03-07
PCT/JP2012/056217 WO2012121403A1 (en) 2011-03-07 2012-03-06 The method of treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
JP2014508715A JP2014508715A (ja) 2014-04-10
JP2014508715A5 true JP2014508715A5 (enExample) 2015-04-02

Family

ID=46798352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540569A Pending JP2014508715A (ja) 2011-03-07 2012-03-06 筋萎縮性側索硬化症の治療方法

Country Status (4)

Country Link
US (1) US20130344081A1 (enExample)
EP (1) EP2683404A4 (enExample)
JP (1) JP2014508715A (enExample)
WO (1) WO2012121403A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2635283T3 (en) * 2010-11-01 2017-04-10 Tact Ip Llc METHODS OF TREATING BRAKE INJURY USING BIOLOGICAL AGENTS
US9539307B2 (en) 2012-09-17 2017-01-10 The Research Institute At Nationwide Children's Hospital Compositions and methods for treating amyotrophic lateral sclerosis
AU2014346987A1 (en) * 2013-11-05 2016-06-23 The Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
CA3100966A1 (en) * 2018-05-25 2019-11-28 Revalesio Corporation Inhibition of neurological disease
WO2020047497A1 (en) 2018-08-31 2020-03-05 Revalesio Corporation Methods and compositions for treating stroke
CN113573778B (zh) * 2018-11-16 2025-05-13 拉帕治疗有限公司 使用诱导性调节性T（iTREG）细胞进行的ALS治疗
US20240245770A1 (en) * 2019-12-16 2024-07-25 The Regents Of The University Of California Compositions and methods for treating neuromuscular disorders
CN114712503B (zh) * 2021-10-09 2023-05-26 浙江大学 c-Abl抑制剂在制备预防和/或治疗肌萎缩性侧索硬化症药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF

Similar Documents

Publication Publication Date Title
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
JP2015125255A5 (enExample)
MX2016011072A (es) Derivado de pirazol amida.
JP2012031178A5 (enExample)
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EP2771031A4 (en) ALPHA SYNNUCLEIN DETECTING HUMANIZED ANTIBODIES
EP2813568A4 (en) MODIFIED FC ANTIBODY REGIONS
EA201201016A1 (ru) Антидоты антикоагулянтов
MX386298B (es) Composicion farmaceutica que comprende adalimumab.
EA201500852A1 (ru) Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP2949647A4 (en) DEUTERATED PHENYLAMINOPYRIMIDIN COMPOUND AND PHARMACEUTICAL COMPOSITION THEREWITH
FR2997852B1 (fr) Composition cosmetique contenant un acetate d'un compose d'aminoacide.
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
WO2015050891A3 (en) Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens
MX392001B (es) Composiciones fertilizantes y métodos para hacer y utilizar las mismas.
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MX386861B (es) Composiciones inhibidoras de nitrificación microencapsuladas.
EP2810659A4 (en) MOUTH-CATCHING TABLET WITH GRANULATE TO COVER THE BITTER TASTE
PH12017500461B1 (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
EP2847218A4 (en) APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
FR3010463B1 (fr) Impulseur de pompe polyphasique avec des moyens d'amplification et de repartition d'ecoulements de jeu.
EP2861571A4 (en) PHENYL ALKYLSULFAMATE COMPOUND AND MUSCLE RELAXANE COMPOSITION THEREWITH
EP2737077A4 (en) DIFFUSION PLATE ASSAY FOR ORITAVANCIN